SCIEX Diagnostics, the in vitro diagnostics division of SCIEX, has formed a joint venture with Zhejiang Dian Diagnostics. The parties plan to jointly establish a joint venture in Hangzhou, China, to develop, register, manufacture and commercialise Class I, II and III in vitro diagnostic reagents for the SCIEX Triple Quad™ 4500MD LC-MS/MS system, that was approved by the China Food and Drug Administration (CFDA) earlier this year.
Mass spectrometry can provide the high sensitivity, specificity and throughput needed in clinical testing areas such as therapeutic drug measurement, vitamin and steroid hormones, and measurements of inherited metabolic diseases, but the lack of readily available IVD assays has made this technology inaccessible to the majority of hospital labs in China where lab-developed tests (LDT) are limited. By combining SCIEX LC-MS/MS and assay development expertise, with Dian’s network and experience, it is expected that the partnership will accelerate China’s clinical laboratory programme and make diagnostic and wellness testing more widespread in the region.
